Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07449780 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Name: A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma — clinical trial record (NCT07449780)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorAkeso

Started2026-03-31

View on ClinicalTrials.gov ↗

Akeso

96 trials monitored

See 1 trial at risk

A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Trial Details

NCT Number	NCT07449780
Lead Sponsor	Akeso
Conditions	Gastric / Gastroesophageal Junction Adenocarcinoma
Enrollment	422 participants
Start Date	2026-03-31
Primary Completion	2027-11-17 (estimated)
Study Completion	2028-02-15 (estimated)
Updated on ClinicalTrials.gov	2026-03-04